<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:a0aff6cb-0ee1-4e06-9e00-6c151bedda43,g:2581a887-7e10-4c64-befe-7c0fc697433f,d:1497b66f641d4414b9dac1fc7f543c5d--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2021" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>angn-20230309</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i2748423d45e5485ab8432b7d0d562c8d_D20230309-20230309" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjE0OTdiNjZmNjQxZDQ0MTRiOWRhYzFmYzdmNTQzYzVkL3NlYzoxNDk3YjY2ZjY0MWQ0NDE0YjlkYWMxZmM3ZjU0M2M1ZF80L2ZyYWc6OGY2ZTNkMzMyY2Q4NGI5OTk0NjNjNDk1ZGY1MDNlMzQvdGFibGU6ZTQyNzZjMzEzZTM5NGE2Y2JiMDNkYWEzOThjYmJkMTYvdGFibGVyYW5nZTplNDI3NmMzMTNlMzk0YTZjYmIwM2RhYTM5OGNiYmQxNl8yLTEtMS0xLTgxMDgz_c5d1d49b-07bb-4399-87a1-49d3be29c06e">0001601485</ix:nonNumeric><ix:nonNumeric contextRef="i2748423d45e5485ab8432b7d0d562c8d_D20230309-20230309" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjE0OTdiNjZmNjQxZDQ0MTRiOWRhYzFmYzdmNTQzYzVkL3NlYzoxNDk3YjY2ZjY0MWQ0NDE0YjlkYWMxZmM3ZjU0M2M1ZF80L2ZyYWc6OGY2ZTNkMzMyY2Q4NGI5OTk0NjNjNDk1ZGY1MDNlMzQvdGFibGU6ZTQyNzZjMzEzZTM5NGE2Y2JiMDNkYWEzOThjYmJkMTYvdGFibGVyYW5nZTplNDI3NmMzMTNlMzk0YTZjYmIwM2RhYTM5OGNiYmQxNl81LTEtMS0xLTgxMDgz_21a65086-9184-4623-afb0-6577d308129c">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="angn-20230309.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i2748423d45e5485ab8432b7d0d562c8d_D20230309-20230309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-09</xbrli:startDate><xbrli:endDate>2023-03-09</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i1497b66f641d4414b9dac1fc7f543c5d_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i2748423d45e5485ab8432b7d0d562c8d_D20230309-20230309" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjE0OTdiNjZmNjQxZDQ0MTRiOWRhYzFmYzdmNTQzYzVkL3NlYzoxNDk3YjY2ZjY0MWQ0NDE0YjlkYWMxZmM3ZjU0M2M1ZF8xL2ZyYWc6YTgxMzg3ZjAwNjQ0NDkzZGE5NWQ1ZTcyZjNkODExOTkvdGV4dHJlZ2lvbjphODEzODdmMDA2NDQ0OTNkYTk1ZDVlNzJmM2Q4MTE5OV8xNTc1_80febef5-6f15-4765-acf2-b9d3c99594e9">8-K</ix:nonNumeric> </span></div><div style="margin-top:12pt;padding-left:108pt;padding-right:108pt;text-align:center"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date of Report (date of earliest event reported): <ix:nonNumeric contextRef="i2748423d45e5485ab8432b7d0d562c8d_D20230309-20230309" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjE0OTdiNjZmNjQxZDQ0MTRiOWRhYzFmYzdmNTQzYzVkL3NlYzoxNDk3YjY2ZjY0MWQ0NDE0YjlkYWMxZmM3ZjU0M2M1ZF8xL2ZyYWc6YTgxMzg3ZjAwNjQ0NDkzZGE5NWQ1ZTcyZjNkODExOTkvdGV4dHJlZ2lvbjphODEzODdmMDA2NDQ0OTNkYTk1ZDVlNzJmM2Q4MTE5OV81NDk3NTU4MTU1MTQ_ca1b26ce-dfd0-490e-a8dc-5d434b982a83">March 9, 2023</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2748423d45e5485ab8432b7d0d562c8d_D20230309-20230309" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjE0OTdiNjZmNjQxZDQ0MTRiOWRhYzFmYzdmNTQzYzVkL3NlYzoxNDk3YjY2ZjY0MWQ0NDE0YjlkYWMxZmM3ZjU0M2M1ZF8xL2ZyYWc6YTgxMzg3ZjAwNjQ0NDkzZGE5NWQ1ZTcyZjNkODExOTkvdGV4dHJlZ2lvbjphODEzODdmMDA2NDQ0OTNkYTk1ZDVlNzJmM2Q4MTE5OV8xNTY5_d699e1c1-e5ab-4a47-89cc-1a27e1d32f2e">ANGION BIOMEDICA CORP.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2748423d45e5485ab8432b7d0d562c8d_D20230309-20230309" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjE0OTdiNjZmNjQxZDQ0MTRiOWRhYzFmYzdmNTQzYzVkL3NlYzoxNDk3YjY2ZjY0MWQ0NDE0YjlkYWMxZmM3ZjU0M2M1ZF8xL2ZyYWc6YTgxMzg3ZjAwNjQ0NDkzZGE5NWQ1ZTcyZjNkODExOTkvdGFibGU6MmE2MDgyOWE1ZjM3NGNjMjlhNDIxZDA0ZTk3NGEyY2IvdGFibGVyYW5nZToyYTYwODI5YTVmMzc0Y2MyOWE0MjFkMDRlOTc0YTJjYl8wLTAtMS0xLTgxMDgz_8448edc3-86a5-45a9-8463-73e7fa4b5769">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="i2748423d45e5485ab8432b7d0d562c8d_D20230309-20230309" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE0OTdiNjZmNjQxZDQ0MTRiOWRhYzFmYzdmNTQzYzVkL3NlYzoxNDk3YjY2ZjY0MWQ0NDE0YjlkYWMxZmM3ZjU0M2M1ZF8xL2ZyYWc6YTgxMzg3ZjAwNjQ0NDkzZGE5NWQ1ZTcyZjNkODExOTkvdGFibGU6MmE2MDgyOWE1ZjM3NGNjMjlhNDIxZDA0ZTk3NGEyY2IvdGFibGVyYW5nZToyYTYwODI5YTVmMzc0Y2MyOWE0MjFkMDRlOTc0YTJjYl8wLTEtMS0xLTgxMDgz_335b068c-4234-4eea-8e63-3d8e3bfb1576">001-39990</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2748423d45e5485ab8432b7d0d562c8d_D20230309-20230309" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE0OTdiNjZmNjQxZDQ0MTRiOWRhYzFmYzdmNTQzYzVkL3NlYzoxNDk3YjY2ZjY0MWQ0NDE0YjlkYWMxZmM3ZjU0M2M1ZF8xL2ZyYWc6YTgxMzg3ZjAwNjQ0NDkzZGE5NWQ1ZTcyZjNkODExOTkvdGFibGU6MmE2MDgyOWE1ZjM3NGNjMjlhNDIxZDA0ZTk3NGEyY2IvdGFibGVyYW5nZToyYTYwODI5YTVmMzc0Y2MyOWE0MjFkMDRlOTc0YTJjYl8wLTItMS0xLTgxMDgz_795545cf-1624-4bdc-8b4e-b19bca915fb4">11-3430072</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></div></td></tr><tr style="height:14pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2748423d45e5485ab8432b7d0d562c8d_D20230309-20230309" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjE0OTdiNjZmNjQxZDQ0MTRiOWRhYzFmYzdmNTQzYzVkL3NlYzoxNDk3YjY2ZjY0MWQ0NDE0YjlkYWMxZmM3ZjU0M2M1ZF8xL2ZyYWc6YTgxMzg3ZjAwNjQ0NDkzZGE5NWQ1ZTcyZjNkODExOTkvdGFibGU6MmE2MDgyOWE1ZjM3NGNjMjlhNDIxZDA0ZTk3NGEyY2IvdGFibGVyYW5nZToyYTYwODI5YTVmMzc0Y2MyOWE0MjFkMDRlOTc0YTJjYl8zLTEtMS0xLTgxMDgz_cf3dcbc2-cdf9-4097-a90f-75f371a3ff5b">7-57 Wells Avenue</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2748423d45e5485ab8432b7d0d562c8d_D20230309-20230309" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjE0OTdiNjZmNjQxZDQ0MTRiOWRhYzFmYzdmNTQzYzVkL3NlYzoxNDk3YjY2ZjY0MWQ0NDE0YjlkYWMxZmM3ZjU0M2M1ZF8xL2ZyYWc6YTgxMzg3ZjAwNjQ0NDkzZGE5NWQ1ZTcyZjNkODExOTkvdGFibGU6MmE2MDgyOWE1ZjM3NGNjMjlhNDIxZDA0ZTk3NGEyY2IvdGFibGVyYW5nZToyYTYwODI5YTVmMzc0Y2MyOWE0MjFkMDRlOTc0YTJjYl80LTEtMS0xLTgxMDgzL3RleHRyZWdpb246ZTIwNWRkMzNjYjRhNDc4ZDlkYjU5YmE0ZGU4YmE2ZWVfNTQ5NzU1ODEzOTAy_5d26d37c-a217-488a-8370-0d48e3aa3b70">Newton</ix:nonNumeric>,  <ix:nonNumeric contextRef="i2748423d45e5485ab8432b7d0d562c8d_D20230309-20230309" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjE0OTdiNjZmNjQxZDQ0MTRiOWRhYzFmYzdmNTQzYzVkL3NlYzoxNDk3YjY2ZjY0MWQ0NDE0YjlkYWMxZmM3ZjU0M2M1ZF8xL2ZyYWc6YTgxMzg3ZjAwNjQ0NDkzZGE5NWQ1ZTcyZjNkODExOTkvdGFibGU6MmE2MDgyOWE1ZjM3NGNjMjlhNDIxZDA0ZTk3NGEyY2IvdGFibGVyYW5nZToyYTYwODI5YTVmMzc0Y2MyOWE0MjFkMDRlOTc0YTJjYl80LTEtMS0xLTgxMDgzL3RleHRyZWdpb246ZTIwNWRkMzNjYjRhNDc4ZDlkYjU5YmE0ZGU4YmE2ZWVfNTQ5NzU1ODEzOTA2_e442ac24-12e3-4233-b44e-4e69ba041330">Massachusetts</ix:nonNumeric> <ix:nonNumeric contextRef="i2748423d45e5485ab8432b7d0d562c8d_D20230309-20230309" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjE0OTdiNjZmNjQxZDQ0MTRiOWRhYzFmYzdmNTQzYzVkL3NlYzoxNDk3YjY2ZjY0MWQ0NDE0YjlkYWMxZmM3ZjU0M2M1ZF8xL2ZyYWc6YTgxMzg3ZjAwNjQ0NDkzZGE5NWQ1ZTcyZjNkODExOTkvdGFibGU6MmE2MDgyOWE1ZjM3NGNjMjlhNDIxZDA0ZTk3NGEyY2IvdGFibGVyYW5nZToyYTYwODI5YTVmMzc0Y2MyOWE0MjFkMDRlOTc0YTJjYl80LTEtMS0xLTgxMDgzL3RleHRyZWdpb246ZTIwNWRkMzNjYjRhNDc4ZDlkYjU5YmE0ZGU4YmE2ZWVfNTQ5NzU1ODEzOTA5_52336ae3-3637-4ba4-8e8e-0f1a14b38370">02459</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices, including zip code )</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i2748423d45e5485ab8432b7d0d562c8d_D20230309-20230309" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjE0OTdiNjZmNjQxZDQ0MTRiOWRhYzFmYzdmNTQzYzVkL3NlYzoxNDk3YjY2ZjY0MWQ0NDE0YjlkYWMxZmM3ZjU0M2M1ZF8xL2ZyYWc6YTgxMzg3ZjAwNjQ0NDkzZGE5NWQ1ZTcyZjNkODExOTkvdGV4dHJlZ2lvbjphODEzODdmMDA2NDQ0OTNkYTk1ZDVlNzJmM2Q4MTE5OV8xNTcw_dfb7b52b-9494-4708-a3ab-c1032cc41a19">415</ix:nonNumeric>) <ix:nonNumeric contextRef="i2748423d45e5485ab8432b7d0d562c8d_D20230309-20230309" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE0OTdiNjZmNjQxZDQ0MTRiOWRhYzFmYzdmNTQzYzVkL3NlYzoxNDk3YjY2ZjY0MWQ0NDE0YjlkYWMxZmM3ZjU0M2M1ZF8xL2ZyYWc6YTgxMzg3ZjAwNjQ0NDkzZGE5NWQ1ZTcyZjNkODExOTkvdGV4dHJlZ2lvbjphODEzODdmMDA2NDQ0OTNkYTk1ZDVlNzJmM2Q4MTE5OV8xNTcx_27c1a310-9407-4c24-9106-ffe45dd79589">655-4899</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant's telephone number, including area code</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2748423d45e5485ab8432b7d0d562c8d_D20230309-20230309" name="dei:WrittenCommunications" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjE0OTdiNjZmNjQxZDQ0MTRiOWRhYzFmYzdmNTQzYzVkL3NlYzoxNDk3YjY2ZjY0MWQ0NDE0YjlkYWMxZmM3ZjU0M2M1ZF8xL2ZyYWc6YTgxMzg3ZjAwNjQ0NDkzZGE5NWQ1ZTcyZjNkODExOTkvdGV4dHJlZ2lvbjphODEzODdmMDA2NDQ0OTNkYTk1ZDVlNzJmM2Q4MTE5OV8xNTcy_f7aba439-2885-4a01-90dd-3250f8378470">&#9744;</ix:nonNumeric> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2748423d45e5485ab8432b7d0d562c8d_D20230309-20230309" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjE0OTdiNjZmNjQxZDQ0MTRiOWRhYzFmYzdmNTQzYzVkL3NlYzoxNDk3YjY2ZjY0MWQ0NDE0YjlkYWMxZmM3ZjU0M2M1ZF8xL2ZyYWc6YTgxMzg3ZjAwNjQ0NDkzZGE5NWQ1ZTcyZjNkODExOTkvdGV4dHJlZ2lvbjphODEzODdmMDA2NDQ0OTNkYTk1ZDVlNzJmM2Q4MTE5OV8xNTY3_2826e0ac-6027-466e-b036-4ee9eccbd847">&#9744;</ix:nonNumeric> </span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2748423d45e5485ab8432b7d0d562c8d_D20230309-20230309" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjE0OTdiNjZmNjQxZDQ0MTRiOWRhYzFmYzdmNTQzYzVkL3NlYzoxNDk3YjY2ZjY0MWQ0NDE0YjlkYWMxZmM3ZjU0M2M1ZF8xL2ZyYWc6YTgxMzg3ZjAwNjQ0NDkzZGE5NWQ1ZTcyZjNkODExOTkvdGV4dHJlZ2lvbjphODEzODdmMDA2NDQ0OTNkYTk1ZDVlNzJmM2Q4MTE5OV8xNTYz_cc1fed98-4773-4cb7-91e2-9eb214982008">&#9744;</ix:nonNumeric> </span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2748423d45e5485ab8432b7d0d562c8d_D20230309-20230309" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjE0OTdiNjZmNjQxZDQ0MTRiOWRhYzFmYzdmNTQzYzVkL3NlYzoxNDk3YjY2ZjY0MWQ0NDE0YjlkYWMxZmM3ZjU0M2M1ZF8xL2ZyYWc6YTgxMzg3ZjAwNjQ0NDkzZGE5NWQ1ZTcyZjNkODExOTkvdGV4dHJlZ2lvbjphODEzODdmMDA2NDQ0OTNkYTk1ZDVlNzJmM2Q4MTE5OV8xNTc0_bbb2e258-00e8-40e5-859b-ff900e96446a">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Title of each class)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Trading Symbol)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Name of exchange on which registered)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2748423d45e5485ab8432b7d0d562c8d_D20230309-20230309" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjE0OTdiNjZmNjQxZDQ0MTRiOWRhYzFmYzdmNTQzYzVkL3NlYzoxNDk3YjY2ZjY0MWQ0NDE0YjlkYWMxZmM3ZjU0M2M1ZF8xL2ZyYWc6YTgxMzg3ZjAwNjQ0NDkzZGE5NWQ1ZTcyZjNkODExOTkvdGFibGU6NmZlMTJhZDY3ODM3NGMxOWE0MDVlYWVkYmYyNmNlYjcvdGFibGVyYW5nZTo2ZmUxMmFkNjc4Mzc0YzE5YTQwNWVhZWRiZjI2Y2ViN18xLTAtMS0xLTgxMDgz_1a88232a-3246-4f48-b723-ad3d6c071be4">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2748423d45e5485ab8432b7d0d562c8d_D20230309-20230309" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjE0OTdiNjZmNjQxZDQ0MTRiOWRhYzFmYzdmNTQzYzVkL3NlYzoxNDk3YjY2ZjY0MWQ0NDE0YjlkYWMxZmM3ZjU0M2M1ZF8xL2ZyYWc6YTgxMzg3ZjAwNjQ0NDkzZGE5NWQ1ZTcyZjNkODExOTkvdGFibGU6NmZlMTJhZDY3ODM3NGMxOWE0MDVlYWVkYmYyNmNlYjcvdGFibGVyYW5nZTo2ZmUxMmFkNjc4Mzc0YzE5YTQwNWVhZWRiZjI2Y2ViN18xLTEtMS0xLTgxMDgz_f936787b-7cc3-41ab-920e-02b743b7a304">ANGN</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2748423d45e5485ab8432b7d0d562c8d_D20230309-20230309" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjE0OTdiNjZmNjQxZDQ0MTRiOWRhYzFmYzdmNTQzYzVkL3NlYzoxNDk3YjY2ZjY0MWQ0NDE0YjlkYWMxZmM3ZjU0M2M1ZF8xL2ZyYWc6YTgxMzg3ZjAwNjQ0NDkzZGE5NWQ1ZTcyZjNkODExOTkvdGFibGU6NmZlMTJhZDY3ODM3NGMxOWE0MDVlYWVkYmYyNmNlYjcvdGFibGVyYW5nZTo2ZmUxMmFkNjc4Mzc0YzE5YTQwNWVhZWRiZjI2Y2ViN18xLTItMS0xLTgxMDgz_333963e3-9765-42c9-87bc-ed4b6387fb14">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2748423d45e5485ab8432b7d0d562c8d_D20230309-20230309" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjE0OTdiNjZmNjQxZDQ0MTRiOWRhYzFmYzdmNTQzYzVkL3NlYzoxNDk3YjY2ZjY0MWQ0NDE0YjlkYWMxZmM3ZjU0M2M1ZF8xL2ZyYWc6YTgxMzg3ZjAwNjQ0NDkzZGE5NWQ1ZTcyZjNkODExOTkvdGV4dHJlZ2lvbjphODEzODdmMDA2NDQ0OTNkYTk1ZDVlNzJmM2Q4MTE5OV8xMzA2_beea286b-9662-4e75-bafe-3090e7f19c4e">&#9746;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2748423d45e5485ab8432b7d0d562c8d_D20230309-20230309" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjE0OTdiNjZmNjQxZDQ0MTRiOWRhYzFmYzdmNTQzYzVkL3NlYzoxNDk3YjY2ZjY0MWQ0NDE0YjlkYWMxZmM3ZjU0M2M1ZF8xL2ZyYWc6YTgxMzg3ZjAwNjQ0NDkzZGE5NWQ1ZTcyZjNkODExOTkvdGV4dHJlZ2lvbjphODEzODdmMDA2NDQ0OTNkYTk1ZDVlNzJmM2Q4MTE5OV8xNTY1_02a4cdc6-a5ef-4b7e-90c1-06fb720cbbbb">o</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1497b66f641d4414b9dac1fc7f543c5d_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.01 Entry into a Material Definitive Agreement.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2023, Angion Biomedica Corp. entered into a Surrender Agreement with NovaPark LLC pursuant to which the parties terminated the Agreement of Lease, dated as of June 21, 2011, as amended, and set to expire in June of 2026, between Angion and NovaPark whereby NovaPark had leased to Angion office and laboratory space at 51 Charles Lindbergh Boulevard, Uniondale, New York (the &#8220;Property&#8221;). Pursuant to the Surrender Agreement: (a) Angion shall pay to NovaPark a termination fee of $3.03 million, and (b) Angion and NovaPark entered into a Membership Interest Redemption Agreement pursuant to which Angion relinquished its 10% membership interest in NovaPark. The Surrender Agreement provides that, except for the payment of the termination fee described above, no other rent or charges (whether or not now accruing or in arrears) will be due from Angion with respect to any period prior to or subsequent to the surrender of the Property to NovaPark, thereby relieving Angion of rent payments equal to approximately $3.86 million, plus other amounts for facility fees and utilities with respect to the Property.  Prior to the entering into the Membership Interest Redemption Agreement, Angion, Itzhak Goldberg, a director and Chairman Emeritus on Angion's Board, and Rina Kurz, Dr. Goldberg&#8217;s spouse, owned 10%, 45% and 45%, respectively, of the membership interests in NovaPark. The transactions were approved by the Audit Committee of Angion&#8217;s Board of Directors as this transaction was a related party transaction. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.02 Termination of a Material Agreement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The information set forth in Item 1.01 hereto is incorporated by reference herein. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i1497b66f641d4414b9dac1fc7f543c5d_13"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:10pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.125%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ANGION BIOMEDICA CORP.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ JAY R. VENKATESAN, M.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date:  March 14, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Jay R. Venkatesan, M.D.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">President and Chief Executive Officer and Director</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "angn-20230309.htm", "description": "8-K", "secsgml_size_bytes": 30803}]
{"company-data": {"conformed-name": "Angion Biomedica Corp.", "cik": "0001601485", "assigned-sic": "2834", "irs-number": "113430072", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-39990", "film-number": "23730669"}, "business-address": {"street1": "51 CHARLES LINDBERGH BOULEVARD", "city": "UNIONDALE", "state": "NY", "zip": "11553", "phone": "(415) 655-4899"}, "mail-address": {"street1": "51 CHARLES LINDBERGH BOULEVARD", "city": "UNIONDALE", "state": "NY", "zip": "11553"}}
angn-20230309
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (date of earliest event reported):
March 9, 2023
ANGION BIOMEDICA CORP.
(Exact name of registrant as specified in its charter)
Delaware
001-39990
11-3430072
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(IRS Employer Identification No.)
7-57 Wells Avenue
Newton
,
Massachusetts
02459
(Address of principal executive offices, including zip code )
(
415
)
655-4899
Registrant's telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
(Title of each class)
(Trading Symbol)
(Name of exchange on which registered)
Common Stock
ANGN
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Item 1.01 Entry into a Material Definitive Agreement.
On March 9, 2023, Angion Biomedica Corp. entered into a Surrender Agreement with NovaPark LLC pursuant to which the parties terminated the Agreement of Lease, dated as of June 21, 2011, as amended, and set to expire in June of 2026, between Angion and NovaPark whereby NovaPark had leased to Angion office and laboratory space at 51 Charles Lindbergh Boulevard, Uniondale, New York (the "Property"). Pursuant to the Surrender Agreement: (a) Angion shall pay to NovaPark a termination fee of $3.03 million, and (b) Angion and NovaPark entered into a Membership Interest Redemption Agreement pursuant to which Angion relinquished its 10% membership interest in NovaPark. The Surrender Agreement provides that, except for the payment of the termination fee described above, no other rent or charges (whether or not now accruing or in arrears) will be due from Angion with respect to any period prior to or subsequent to the surrender of the Property to NovaPark, thereby relieving Angion of rent payments equal to approximately $3.86 million, plus other amounts for facility fees and utilities with respect to the Property.  Prior to the entering into the Membership Interest Redemption Agreement, Angion, Itzhak Goldberg, a director and Chairman Emeritus on Angion's Board, and Rina Kurz, Dr. Goldberg's spouse, owned 10%, 45% and 45%, respectively, of the membership interests in NovaPark. The transactions were approved by the Audit Committee of Angion's Board of Directors as this transaction was a related party transaction.
Item 1.02 Termination of a Material Agreement.
The information set forth in Item 1.01 hereto is incorporated by reference herein.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ANGION BIOMEDICA CORP.
By:
/s/ JAY R. VENKATESAN, M.D.
Date:  March 14, 2023
Jay R. Venkatesan, M.D.
President and Chief Executive Officer and Director